Currently out of the existing stock ratings of Rohin Patel, 5 are a BUY (83.33%), 1 are a HOLD (16.67%).

Rohin Patel

Work Performance Price Targets & Ratings Chart

Analyst Rohin Patel, currently employed at JPMORGAN, has had 50% of price targets met with an average potential upside of 25.74%, reached in 211 days on average.

Rohin Patel has documented 11 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NPCE, Neuropace at 13-Nov-2026.

Wall Street Analyst Rohin Patel

Analyst best performing recommendations are on HAE (HAEMONETICS).
The best stock recommendation documented was for HAE (HAEMONETICS) on 12/12/2025. The price target of $74 was fulfilled within 34 days with a profit of $9.49 (11.37%), with a performance score of 3.34.

Average potential price target upside

HAE Haemonetics NPCE Neuropace

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 08-Nov-2017

$145

$24.84 (20.67%)

$140

16 days ago
(06-Nov-2026)

43/46 (93.48%)

$25.07 (20.90%)

393

Buy Since 10-Sep-2024

$142

$21.84 (18.18%)

$130

17 days ago
(05-Nov-2026)

12/14 (85.71%)

$17.89 (14.41%)

267

Buy Since 26-Nov-2013

$140

$19.84 (16.51%)

$90

1 months 13 days ago
(09-Oct-2026)

34/44 (77.27%)

$21.31 (17.95%)

444

Hold Since 06-Feb-2026

$123

$2.84 (2.36%)

$92

2 months 5 days ago
(17-Sep-2026)

24/24 (100%)

$15.4 (14.31%)

142

Buy Since 16-Aug-2021

$125

$4.84 (4.03%)

$90

2 months 19 days ago
(03-Sep-2026)

12/12 (100%)

$22.15 (21.54%)

372

Show more analysts

Please expand the browser size to see the chart

Which stock is Rohin Patel most bullish on?

Potential upside of $1.05 has been obtained for NPCE (NEUROPACE)

What Year was the first public recommendation made by Rohin Patel?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?